- Home
- LOCO vs CRVS Comparison
LOCO vs CRVS Comparison
Compare LOCO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- CRVS
- Stock Information
- Founded
- LOCO 1980
- CRVS 2014
- Country
- LOCO United States
- CRVS United States
- Employees
- LOCO N/A
- CRVS N/A
- Industry
- LOCO Restaurants
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- CRVS Health Care
- Exchange
- LOCO Nasdaq
- CRVS Nasdaq
- Market Cap
- LOCO 323.7M
- CRVS 305.4M
- IPO Year
- LOCO 2014
- CRVS 2016
- Fundamental
- Price
- LOCO $10.63
- CRVS $5.75
- Analyst Decision
- LOCO Buy
- CRVS Strong Buy
- Analyst Count
- LOCO 2
- CRVS 4
- Target Price
- LOCO $18.00
- CRVS $15.00
- AVG Volume (30 Days)
- LOCO 175.1K
- CRVS 518.7K
- Earning Date
- LOCO 10-30-2025
- CRVS 08-07-2025
- Dividend Yield
- LOCO N/A
- CRVS N/A
- EPS Growth
- LOCO N/A
- CRVS N/A
- EPS
- LOCO 0.85
- CRVS N/A
- Revenue
- LOCO $479,690,000.00
- CRVS N/A
- Revenue This Year
- LOCO $6.29
- CRVS N/A
- Revenue Next Year
- LOCO $1.56
- CRVS N/A
- P/E Ratio
- LOCO $12.53
- CRVS N/A
- Revenue Growth
- LOCO 1.85
- CRVS N/A
- 52 Week Low
- LOCO $8.29
- CRVS $2.54
- 52 Week High
- LOCO $14.10
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- LOCO 52.39
- CRVS 65.10
- Support Level
- LOCO $10.40
- CRVS $5.28
- Resistance Level
- LOCO $10.74
- CRVS $5.64
- Average True Range (ATR)
- LOCO 0.26
- CRVS 0.30
- MACD
- LOCO 0.04
- CRVS 0.03
- Stochastic Oscillator
- LOCO 75.57
- CRVS 77.70
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).